Nakachi, Kohei

Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research

Immunotherapy and Immune ResponsesHepatocellular Carcinoma Treatment and Prognosis

Cited by 302

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., et al. (2023) · The Lancet

Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct Disorders

Cited by 258

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients

Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology

Hepatocellular Carcinoma Treatment and PrognosisImmunotherapy and Immune Responses

Cited by 178

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

Peretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., et al. (2015) · Journal of Gastroenterology

Hepatocellular Carcinoma Treatment and PrognosisHepatitis C virus research

Cited by 90